Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y

Human Vaccines

Volumn 7, Issue 12, 2011, Pages 1343-1358

  Einstein, Mark H ^a   Baron, Mira ^b   Levin, Myron J ^c   Chatterjee, Archana ^d   Fox, Bradley ^e   Scholar, Sofia ^f   Rosen, Jeffrey ^g   Chakhtoura, Nahida ^h   Meric, Dorothée ⁱ   Dessy, Francis J ⁱ   Datta, Sanjoy K ⁱ   Descamps, Dominique ⁱ   Dubin, Gary ^j  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Rapid Medical Research   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Liberty Family Practice   (United States)

^f Walla Walla Clinic   (United States)

^g Clinical Research of South Florida   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Cervarix ; Gardasil ; Human papillomavirus; Immunogenicity; Safety

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PLACEBO; WART VIRUS VACCINE;

ADULT; AGE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BRONCHITIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION PREVENTION; MEMORY CELL; MULTICENTER STUDY; NORMAL HUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEROLOGY; VACCINATION; VAGINA SECRETION;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84855181757     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.12.18281     Document Type: Article

References (47)

1. Castellsagué X, de Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, et al. HPV and cervical cancer in the world. Vaccine 2007; 25:1-230; PMID:18068032.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108; PMID:15761078; DOI:10.3322/canjclin.55.2.74.
3. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65; PMID:11919208; DOI:10.1136/jcp.55.4.244.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; DOI:10.1002/(SICI)1096-9896(199909)189: 1〈12::AID-PATH431〉3.0.CO;2-F.
5. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de SS, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26:1-16; PMID:18847553; DOI:10.1016/j.vaccine. 2008.05.064.
6. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49; PMID:16828940; DOI:10.1016/j.vaccine.2006. 06.005.
7. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008; 68:359-72; PMID:18257611; DOI:10.2165/00003495-200868030-00007.
8. Caulfield MJ, Shi L, Wang S, Wang B, Tobery TW, Mach H, et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin 2007; 3:139-45; PMID:17581283; DOI:10.4161/hv.3.4.4309.
9. Tovar JM, Bazaldua OV. New quadrivalent HPV vaccine developments. Postgrad Med 2008; 120:14-6; PMID:19020361; DOI:10.3810/pgm.2008.11.1929.
10. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; DOI:10.1016/S0140-6736(07)60946-5.
11. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196:1438-46; PMID:18008221; DOI:10.1086/522864.
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; DOI:10.1056/NEJMoa061741.
13. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; DOI:10.1016/S0140-6736(09)61248-4.
14. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65; PMID:15541448; DOI:10.1016/S0140- 6736(04)17398-4.
15. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006; 367:1247-55; PMID:16631880; DOI:10.1016/S0140-6736(06)68439-0.
16. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9; PMID:17499406; DOI:10.1016/j.vaccine. 2007.03.049.
17. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; DOI:10.1016/S1470-2045(05)70101-7.
18. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66; PMID:17117182; DOI:10.1038/sj.bjc.6603469.
19. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27:5612-9; PMID:19647066; DOI:10.1016/j.vaccine.2009. 07.027.
20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8; PMID:9459645; DOI:10.1056/NEJM199802123380703.
21. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8; PMID:9217656; DOI:10.1016/S0002-9343(97)00177-0.
22. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-6; PMID:11410191; DOI:10.1016/S0140-6736(00)04956-4.
23. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32:16-24; PMID:15753008; DOI:10.1016/j.jcv.2004. 12.008.
24. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008; 105:5850-5; PMID:18413606; DOI:10.1073/pnas.0800868105.
25. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110:1-10; PMID:18653222; DOI:10.1016/j.ygyno.2008. 05.036.
26. Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res 2009; 130:266-76; PMID:19901436.
27. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553-7; PMID:8524802; DOI:10.1073/pnas.92.25.11553.
28. World Health Organization. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. World Health Organization 2007 Available from: URL:http://whqlibdoc.who.int/hq/2007/WHO-IVB- 07.05-eng. pdf
29. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-71; PMID:19519255; DOI:10.1086/599988.
30. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19; PMID:19684472; DOI:10.4161/hv.5.10.9518.
31. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51; PMID:18930097; DOI:10.1016/j. vaccine.2008.09.073.
32. Moscicki AB, Wheeler C, Romanowski B, Hedrick J, Gall S, Ferris D, et al. Anamnestic response elicited by a fourth dose of the HPV-16/18 adjuvanted vaccine in young women. EUROGIN, Monte Carlo, Monaco, February 17-20, 2010. 2010.
33. th Biennial Meeting, Prague, Czech Republic, October 23-26, 2010. 2010.
34. th International Papillomavirus Conference, Montreal, Canada, July 3-8, 2010. 2010.
35. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006; 24:Suppl 3:S3/106-13; PMID:16949996; DOI:10.1016/j.vaccine.2006.05.110.
36. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581-7; PMID:19022320; DOI:10.1016/j.vaccine.2008.10.088.
37. Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630-8; PMID:18845199; DOI:10.1016/j. vaccine.2008.09.049.
38. Garçon N, Chomez P, Van MM. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; DOI:10.1586/14760584.6.5.723.
39. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596; DOI:10.4049/jimmunol. 0901474.
40. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95; PMID:15454922; DOI:10.1038/ni1112.
41. Dessy F, Poncelet S, Xhenseval V, Méric S, Datta S, on behalf of the HPV-010 study group. Comparative evaluation of the immunogenicity of two prophylactic human papillomavirus cervical cancer vaccines by Merck's competitive Luminex immunoassay (cLIA) and GSK's binding ELISA. EUROGIN, Monte Carlo, Monaco, February 17-20, 2010. 2010.
42. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; DOI:10.4161/hv.4.6.6912.
43. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26:53-61; PMID:18847557; DOI:10.1016/j. vaccine.2008.06.002.
44. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55; PMID:20643092; DOI:10.1016/j. vaccine.2010.07.007.
45. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11:1118-24; PMID:16186818; DOI:10.1038/nm1292.
46. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005; 11:1113-7; PMID:16186817; DOI:10.1038/nm1293.
47. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131-7; PMID:12925846; DOI:10.1038/nm917.